Vincent Verbruggen fd37421245 Init

2025-10-25 20:11:21 +02:00

..

Comparative efficacy safety.pdf

Init

2025-10-25 20:11:21 +02:00

Diabetes Obesity Metabolism - 2024 - Neeland - Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and.pdf

Init

2025-10-25 20:11:21 +02:00

Diabetes Obesity Metabolism - 2025 - Look - Body composition changes during weight reduction with tirzepatide in the.pdf

Init

2025-10-25 20:11:21 +02:00

Effects of GLP-1 Receptor Agonists on Lean Body Mass and Muscle Health.pdf

Init

2025-10-25 20:11:21 +02:00

Glucagon-like peptide-1 receptor, mechanisms and advances in therapy.pdf

Init

2025-10-25 20:11:21 +02:00

Notes.md

Init

2025-10-25 20:11:21 +02:00

Once-Weekly Semaglutide in Adults with Overweight or Obesity.pdf

Init

2025-10-25 20:11:21 +02:00

Ozempic and GLP-1 Agonists for Weight Loss_ Side Effects Overview.pdf

Init

2025-10-25 20:11:21 +02:00

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.pdf

Init

2025-10-25 20:11:21 +02:00

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.pdf

Init

2025-10-25 20:11:21 +02:00